Experience with second-line trabectedin in daily clinical practice: case studies.

Abstract

As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female patient with metastatic leiomyosarcoma maintained disease control for 2 years with trabectedin (× 41 cycles) with excellent tolerability and no relevant adverse events. At the time of writing, a male patient with a metastatic solitary fibrous tumor was asymptomatic after 30 cycles of trabectedin and treatment was ongoing. A young male patient with a recurrent, nonresectable, retroperitoneal myxoid/round cell liposarcoma was able to continue his sporting activities (triathlons) over 2 years with trabectedin (× 14 cycles) plus watchful waiting.

• Authors: Javier Martín-Broto, Nadia Hindi, Giovanni Grignani, Alessandra Merlini, Tony Ibrahim, Axel Le Cesne
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 30s Pg. 23-32 (Sep 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 36200932 (Publication Type: Journal Article)

Chemical References

• Trabectedin
• Antineoplastic Agents, Alkylating
• Tetrahydroisoquinolines
• Dioxoles

Topics

• Humans
• Male
• Female
• Adult
• Trabectedin (adverse effects)
• Quality of Life
• Antineoplastic Agents, Alkylating (adverse effects)
• Neoplasm Recurrence, Local (drug therapy)
• Sarcoma (drug therapy)
• Liposarcoma (drug therapy)
• Tetrahydroisoquinolines (adverse effects)
• Dioxoles (adverse effects)